Sign inCreate account

Report workspace tools

NCT06318169RECRUITINGanonymous

A Phase 3 Study to Evaluate the Efficacy and Safety of Pegozafermin in Subjects With Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis

Sponsor

Source record

89bio, Inc.

Phase

Source record

PHASE3

Modality

AI-normalized

protein therapy

Target

AI-normalized

Pegozafermin, Placebo

Indication / condition

AI-normalized

Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH) / Nonalcoholic Steatohepatitis (NASH) With Fibrosis

Intervention

Source record

Pegozafermin, Placebo

Source & freshness

Source record

NCT ID

NCT06318169

Original source

ClinicalTrials.gov

Source last updated

Jun 04, 2026

Ingested at

May 23, 2026

Internal sync

May 23, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT06318169

Title

A Phase 3 Study to Evaluate the Efficacy and Safety of Pegozafermin in Subjects With Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis

Sponsor

89bio, Inc.

Status

RECRUITING

Phase

PHASE3

Condition raw

Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH) / Nonalcoholic Steatohepatitis (NASH) With Fibrosis

Condition normalized

Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH) / Nonalcoholic Steatohepatitis (NASH) With Fibrosis

Modality raw

protein therapy

Modality normalized

protein therapy

Target raw

Pegozafermin, Placebo

Target normalized

Pegozafermin, Placebo

Interventions

Pegozafermin, Placebo

Public preview

Source record

A Phase 3 Study to Evaluate the Efficacy and Safety of Pegozafermin in Subjects With Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis is a PHASE3 clinical asset sponsored by 89bio, Inc. in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH) / Nonalcoholic Steatohepatitis (NASH) With Fibrosis. SEO and diligence focus: Pegozafermin, Placebo, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

A Phase 3 Study to Evaluate the Efficacy and Safety of Pegozafermin in Subjects With Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT06318169

Status

RECRUITING

Phase

PHASE3

Sponsor

89bio, Inc.

Executive brief

Investment-Ready Snapshot

A Phase 3 Study to Evaluate the Efficacy and Safety of Pegozafermin in Subjects With Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis is a PHASE3 clinical asset sponsored by 89bio, Inc. in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH) / Nonalcoholic Steatohepatitis (NASH) With Fibrosis. SEO and diligence focus: Pegozafermin, Placebo, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedJun 04, 2026
Internal syncMay 23, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT06318169

Indication

Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH) / Nonalcoholic Steatohepatitis (NASH) With Fibrosis

Modality

protein therapy

Target

Pegozafermin, Placebo

Intervention

Pegozafermin, Placebo

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.